Information on this website is exclusively for health care professionals and not the general public.
Are you a qualified Secondary-Care Pharmacist or healthcare professional?
Benefits and cost-effectiveness of Nivestim™ for febrile neutropenia
Hospital Pharmacy Europe Issue 62 May/June 2012
Biosimilar medicines have emerged as potentially cost-effective alternatives to originator products. This review focuses on Nivestim™, a filgrastim biosimilar approved for the treatment of febrile neutropenia
You must login to continue reading this article
Log in to Hospital Pharmacy Europe
Forgotten your password? Click this button and we will send you a reminder by email.
Not yet registered?
Need advice? Try the help section.